Research graph
References from Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL. Local targets link to admitted publications; unresolved targets remain external evidence.
Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups
10.1200/jco.22.02705 · 2023 · External reference
Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia
10.1200/jco.2011.34.8144 · 2011 · External reference
TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children
10.1200/jco.2017.75.5215 · 2018 · External reference
Distinct prognostic effects of TP53 mutations in newly diagnosed versus relapsed/refractory (R-R) patients (pts) with B-acute lymphoblastic leukemia (ALL) treated with mini-Hcvd-inotuzumab ozogamicin with or without blinatumomab regimens
10.1182/blood-2020-142012 · 2020 · External reference
Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy
2024 · External reference
Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy
10.1200/jco.21.02143 · 2022 · External reference
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
10.1182/bloodadvances.2020001466 · 2020 · External reference
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
10.1038/s44321-024-00024-2 · 2024 · External reference
Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing
10.1080/10428194.2017.1390232 · 2018 · External reference
Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment
10.1182/blood-2010-11-320309 · 2011 · External reference
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
10.1182/blood-2016-09-738070 · 2017 · External reference
Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children
10.1038/s41375-020-0831-z · 2020 · External reference
Overcoming intrinsic resistance of cancer cells to CAR T-cell killing
10.1158/1078-0432.ccr-21-1559 · 2021 · External reference
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
10.1084/jem.188.11.2033 · 1998 · External reference
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
10.1038/ng1097-141 · 1997 · External reference
Apoptosis - the p53 network
10.1242/jcs.00739 · 2003 · External reference
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity
10.1182/blood.2019002121 · 2020 · External reference
Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction
10.1158/2159-8290.cd-19-0813 · 2020 · External reference
Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation
10.1182/bloodadvances.2022009543 · 2023 · External reference
Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
10.1038/s41419-023-05829-6 · 2023 · External reference
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
10.1038/s41392-022-00915-1 · 2022 · External reference
Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax
10.1038/s41388-022-02196-y · 2022 · External reference
